Outcome of Immune Checkpoint Inhibitor and Molecular Target Agent Combination for Advanced Hepatocellular Carcinoma: Beyond Sorafenib Era | Zendy

AI Assistant Blog Pricing

Open Access

Outcome of Immune Checkpoint Inhibitor and Molecular Target Agent Combination for Advanced Hepatocellular Carcinoma: Beyond Sorafenib Era

Author(s) -

NaeYun Heo

Publication year - 2021

Publication title -

korean journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.203

H-Index - 25

eISSN - 2233-6869

pISSN - 1598-9992

DOI - 10.4166/kjg.2021.013

Subject(s) - sorafenib , hepatocellular carcinoma , medicine , oncology , immune checkpoint , cancer research , pharmacology , immunotherapy , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.